Brief: Avidity Biosciences Receives FDA Breakthrough Therapy Designation For Duchenne Muscular Dystrophy Treatment
23/07/2025 14:10
July 23 (Reuters) - Avidity Biosciences Inc RNA.O: AVIDITY BIOSCIENCES RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DELPACIBART ZOTADIRSEN (DEL-ZOTA) FOR THE TREATMENT OF DMD IN PEOPLE WITH MUTATIONS AMENABLE TO EXON 44 SKIPPING AVIDITY BIOSCIENCES INC - ON TRACK FOR BLA SUBMISSION FOR DEL-ZOTA BY YEAR-END 2025 AVIDITY BIOSCIENCES INC - DEL-ZOTA SHOWS SIGNIFICANT INCREASES IN EXON SKIPPING AND DYSTROPHIN Source text: ID:nPn5F3sRSa Further company coverage: RNA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avidity Biosciences
See all newsFactbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off